vTv Therapeutics Receives FDA Orphan Drug Designation for Sickle Cell Treatment

Key Facts

vTv Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its HPPD program for the treatment of sickle cell disease. According to a company statement on GlobeNewswire, the designation supports efforts to secure partners for the HPPD program while the company focuses its resources on cadisegliatin, its late-stage treatment for type 1 diabetes.

VTVT closed at $30.03 on October 6, 2026, after reaching a day high of $30.5 and a low of $29.55. This regulatory milestone provides the company with financial and regulatory incentives as it continues to advance its clinical pipeline and strategic partnership discussions.